Proteo Inc./ Proteo Biotech AG: Proteo's Elafin Will Be Tested at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)

IRVINE, Calif.--(BUSINESS WIRE)--Proteo, Inc. (OTCBB:PTEO; Frankfurter Freiverkehr: WKN: 925981) and its wholly-owned subsidiary Proteo Biotech AG announced today the signing of a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). Under the agreement Proteo will provide USAMRIID with Elafin and related scientific data in order to plan and conduct preclinical research on the development of new therapeutic strategies to combat life-threatening infectious diseases.